July 11, 2024 01:39 PM EDT

Illumina competitor Element Biosciences raises $277M in Series D

Jared Whitlock

Features Editor

Element Biosciences has raised an additional $277 million in private financing to support commercialization of its benchtop DNA sequencer and an instrument launch as the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Illumina competitor Element Biosciences raises $277M in Series D

Jared Whitlock

Features Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

Il­lu­mi­na com­peti­tor El­e­ment Bio­sciences rais­es $277M in Se­ries D

Features Editor

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Illumina competitor Element Biosciences raises $277M in Series D